Form 4: Baker Bros. Advisors LP Acquires Stock Options in IGM Biosciences

Baker Bros. Advisors LP, along with related entities and individuals, reported the acquisition of non-qualified stock options in IGM Biosciences, Inc. on March 12, 2024.

Summary

• Baker Bros. Advisors LP, along with related entities and individuals including Felix J. Baker and Julian C. Baker, filed a Form 4 regarding transactions in IGM Biosciences, Inc. (IGMS).
• On March 12, 2024, Felix J. Baker was granted 29,400 non-qualified stock options exercisable into common stock of IGMS under the company's Amended and Restated 2018 Omnibus Incentive Plan.
• The stock options have a strike price of $9.95 per share and vest monthly following the Issuer's 2024 Annual Meeting of Stockholders, subject to continued service on the board.
• The options expire on March 12, 2034, subject to earlier termination as provided in the plan.
• Felix J. Baker serves on the board as a representative of Baker Brothers Life Sciences, L.P. and 667, L.P., and the funds are entitled to receive all the pecuniary interest in the securities issued.
• Baker Bros. Advisors LP has voting and dispositive power over the stock options and any common stock acquired as a result of the exercise of the stock options.
• The reporting persons are deemed directors by deputization of the Issuer.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The fact that a major shareholder and director is receiving stock options could be interpreted as a mildly positive signal, suggesting confidence in the company's future.

Positives

• The acquisition of stock options by a director and significant shareholder like Baker Bros. Advisors LP could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The stock options vest monthly following the Issuer's 2024 Annual Meeting of Stockholders, subject to Felix J. Baker's continued service on the board, or fully vest if the Issuer's 2025 Annual Meeting of Stockholders is prior to the one-year anniversary of the 2024 Annual Meeting.

Management Comments

• Felix J. Baker serves on the Board as a representative of Baker Brothers Life Sciences, L.P. and 667, L.P.

Industry Context

Form 4 filings are routine disclosures required by the SEC when insiders of a publicly traded company buy or sell the company's securities. This filing indicates changes in beneficial ownership by Baker Bros. Advisors LP, a significant shareholder and a director of IGM Biosciences.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry to align their interests with those of shareholders.
• The vesting schedule and expiration date of these options are typical for such grants.
• Baker Bros. Advisors LP is a well-known investment firm specializing in life sciences, and their investment decisions are often closely watched by other investors in the sector.

Stakeholder Impact

• The grant of stock options to a director could potentially align the director's interests more closely with those of shareholders.
• The transaction itself has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates